Further details of the therapeutic benefits of Boehringer Ingelheim GmbH/Eli Lilly and Company’s SGLT2 inhibitor, Jardiance (empagliflozin), in patients with heart failure, presented at the virtual annual meeting of the European College of Cardiology (ESC) at the weekend, will likely add fuel to a forthcoming marketing battle between a number of big pharma companies marketing SGLT2 inhibitors.
Heart Failure A Key Future Market For Jardiance?
EMPEROR-Reduced Underscores SGLT2 Benefits
Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) reduces cardiovascular deaths and hospitalizations in certain heart failure patients regardless of whether they have diabetes, and regulatory submissions are expected for the additional indication later this year.

More from Cardiovascular
Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
More from Therapy Areas
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.